Cytokeratin 19 Antibody (A53-B/A2.26), Novus Biologicals™

Cytokeratin 19

Monoclonal

0.2mg/mL

Western Blot 0.5-1ug/ml, Simple Western 10 ug/ml, Flow Cytometry 0.5-1ug/million cells, ELISA 1-5ug/ml for coating, Immunocytochemistry/Immunofluorescence 1-2ug/ml, Immunoprecipitation 1-2ug/500ug protein lysate, Immunohistochemistry-Paraffin 0.5-1ug/ml, Immunohistochemistry-Frozen 0.5-1ug/ml

P08727

KRT19

Human breast cancer MCF-7 cells were used as the immunogen for the Keratin-19 antibody.

0.2 mg

Cancer, Cell Biology, Cellular Markers, Cytoskeleton Markers, Neuroscience, Stem Cell Markers

3880

Human

Purified

Western Blot, Flow Cytometry, ELISA, Immunocytochemistry, Immunofluorescence, Immunoprecipitation

A53-B/A2.26

Unconjugated

PBS with 0.05% BSA. with 0.05% Sodium Azide

CK19, CK-19, cytokeratin 19, Cytokeratin-19,40-kDa keratin intermediate filament, K19cytokeratin-19, K1CS, keratin 19, keratin, type I cytoskeletal 19, keratin, type I, 40-kd, keratin-19, MGC15366

Mouse

Protein G purified

RUO

Primary

This MAb reacts with the rod domain of human cytokeratin-19 (CK19), a polypeptide of 40kDa. Its epitope maps between amino acid 312-335. CK19 is expressed in sweat gland, mammary gland ductal and secretory cells, bile ducts, gastrointestinal tract, bladder urothelium, oral epithelia, esophagus, and ectocervical epithelium. Anti-CK19 reacts with a wide variety of epithelial malignancies including adenocarcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast. Perhaps the most useful application is the identification of thyroid carcinoma of the papillary type, although 50%-60% of follicular carcinomas are also labeled. Anti-CK19 is a useful marker for detection of tumor cells in lymph nodes, peripheral blood, bone marrow and breast cancer.

Store at 4C.

IgG2a κ